174 related articles for article (PubMed ID: 31081077)
1. LINC01308 accelerates the malignant progression of ovarian cancer by binding to miRNA-506.
Zhang YY; Li P; Zhu MZ; Guo Y; Yang J
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3253-3260. PubMed ID: 31081077
[TBL] [Abstract][Full Text] [Related]
2. LncRNA SNHG12 accelerates the progression of ovarian cancer via absorbing miRNA-129 to upregulate SOX4.
Sun D; Fan XH
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2345-2352. PubMed ID: 30964158
[TBL] [Abstract][Full Text] [Related]
3. MiRNA-96 accelerates the malignant progression of ovarian cancer via targeting FOXO3a.
Yang N; Zhang Q; Bi XJ
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):65-73. PubMed ID: 31957819
[TBL] [Abstract][Full Text] [Related]
4. Lnc00908 promotes the development of ovarian cancer by regulating microRNA-495-5p.
Jiang JN; Hong QY; Gao HJ; Lai BL; Lan JF; Yang Q
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1388-1396. PubMed ID: 30840259
[TBL] [Abstract][Full Text] [Related]
5. LncRNA DANCR aggravates the progression of ovarian cancer by downregulating UPF1.
Pei CL; Fei KL; Yuan XY; Gong XJ
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10657-10663. PubMed ID: 31858532
[TBL] [Abstract][Full Text] [Related]
6. LncRNA GIHCG promotes development of ovarian cancer by regulating microRNA-429.
Yao N; Yu L; Zhu B; Gan HY; Guo BQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8127-8134. PubMed ID: 30556850
[TBL] [Abstract][Full Text] [Related]
7. LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating KLF4.
Zhang C; Liu J; Zhang Y; Luo C; Zhu T; Zhang R; Yao R
Biomed Pharmacother; 2019 Nov; 119():109431. PubMed ID: 31514068
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MIF-AS1 aggravates the progression of ovarian cancer by sponging miRNA-31-5p.
Fan Y; Wang L; Han XC; Ma HY; Zhang N; Zhe L
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2248-2255. PubMed ID: 32196575
[TBL] [Abstract][Full Text] [Related]
9. LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer.
Zheng W; Tian X; Cai L; Shen YM; Cao QS; Yang JY; Tian GY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10443-10452. PubMed ID: 31841198
[TBL] [Abstract][Full Text] [Related]
10. CircRNA UBAP2 promotes the progression of ovarian cancer by sponging microRNA-144.
Sheng M; Wei N; Yang HY; Yan M; Zhao QX; Jing LJ
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7283-7294. PubMed ID: 31539115
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA PVT1 promotes cell proliferation and invasion through regulating miR-133a in ovarian cancer.
Yang Q; Yu Y; Sun Z; Pan Y
Biomed Pharmacother; 2018 Oct; 106():61-67. PubMed ID: 29957467
[TBL] [Abstract][Full Text] [Related]
12. LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186.
Luo X; Song Y; Tang L; Sun DH; Ji DG
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7788-7797. PubMed ID: 30536320
[TBL] [Abstract][Full Text] [Related]
13. LncRNA HANR aggravates the progression of non-small cell lung cancer via mediating miRNA-140-5p.
Li SJ; Wu YX; Liang YH; Gao Y; Wu AB; Zheng HY; Yang ZX
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):704-711. PubMed ID: 32016972
[TBL] [Abstract][Full Text] [Related]
14. MiR-574-3p exerts as a tumor suppressor in ovarian cancer through inhibiting MMP3 expression.
Zheng J; Zhou Y; Li XJ; Hu JM
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6839-6848. PubMed ID: 31486483
[TBL] [Abstract][Full Text] [Related]
15. LncSNHG16 promotes proliferation and migration of osteosarcoma cells by targeting microRNA-146a-5p.
Zheng SN; Ge DW; Tang J; Yang J; Yan JW; Qiu JJ; Yin ZW; Ni Y; Zhao L; Chen X; Yang L
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):96-104. PubMed ID: 30657551
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of LncRNA FOXC2-AC1 promoting lung cancer metastasis by regulating miR-107.
Wu XF; Lu JT; Chen W; Wang N; Meng JC; Zhou YH
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):690-698. PubMed ID: 30720176
[TBL] [Abstract][Full Text] [Related]
17. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652.
Zhao Y; Hu Y; Shen Q; Chen Q; Zhu XJ; Jiang SS; Zhang Q
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5281-5291. PubMed ID: 32495861
[TBL] [Abstract][Full Text] [Related]
18. MiRNA-8073 targets ZnT1 to inhibit malignant progression of ovarian cancer.
Zhang L; Wang YH; Wang L
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6062-6069. PubMed ID: 31364107
[TBL] [Abstract][Full Text] [Related]
19. MiRNA-199 inhibits malignant progression of lung cancer through mediating RGS17.
Su WZ; Ren LF
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3390-3400. PubMed ID: 31081094
[TBL] [Abstract][Full Text] [Related]
20. LncRNA DLEU1 accelerates the malignant progression of clear cell renal cell carcinoma via regulating miRNA-194-5p.
He GZ; Yu SY; Zhou QP; Chen ML; Zhang YW; Zheng Y; Zhang ZB; Han ZY; Yu J
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10691-10698. PubMed ID: 31858537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
